27 July 2026 Sydney, Australia

Nyrada Quarterly Activities Report & Appendix 4C

Highlights:

- Xolatryp® Program
  - First patient dosed in Phase IIa clinical trial to assess safety and preliminary efficacy of Xolatryp® in reducing heart tissue damage and improving heart function in patients suffering a heart attack.
  - Nepean Hospital (NSW) and Sir Charles Gairdner Hospital (WA) activated in Phase IIa clinical trial.
  - Xolatryp demonstrated anti-tumour efficacy and doxorubicin treatment enhancement in preclinical study.
  - Pilot study demonstrated cardioprotection from doxorubicin-induced cardiomyopathy.
  - Pre-IND meeting with US FDA requested.
- Finance, Capital, and Corporate
  - Sound financial position with a cash balance of AU$8.39 million at 30 June 2026.
  - R&D tax rebate in amount of AU$2.46 million received.
  - Option exercise proceeds in amount of AU$0.83 million received.
  - US Patent Office Notice of Allowance received.

Nyrada Inc (ASX:NYR), a clinical stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today announces its Quarterly Activities Report and Appendix 4C for the three months ending 30 June 2026.

Xolatryp® Program

Phase IIa Clinical Trial

Nyrada's PROTECT-MI Phase IIa clinical trial continues to advance and remains on track for completion in CY2027, with the final patient expected to be dosed in mid-2027. Following last patient dosing and a 30-day follow-up visit, top-line results are anticipated within approximately three months thereafter.

Shortly following the conclusion of the quarter, Nyrada announced that the first patient in its Phase IIa Clinical Trial had been dosed.

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

Nepean Hospital (NSW) was activated early in the quarter, enabling patient recruitment. Sir Charles Gairdner Hospital (WA) was activated shortly following the conclusion of the quarter. Research governance office (RGO) approval for five other sites within Australia is progressing and discussions are also advancing with additional sites across Australia and New Zealand.

Nyrada actively monitors recruitment performance across all trial sites and, subject to local RGO approvals, retains the flexibility to bring on additional sites and concentrate resources where recruitment potential is strongest.

Regulatory

Nyrada is preparing an investigational new drug (IND) application to submit to the US FDA. A pre-IND meeting with the Agency has been requested with the IND application to be submitted prior to the conclusion of CY2026.

Research and Development

During the quarter, the Company announced the results of two preclinical studies related to determining the potential utility and efficacy of Xolatryp in oncology.

In the first study, Xolatryp demonstrated clear anti-tumour activity in a preclinical model of liver cancer, both as a monotherapy and in combination with doxorubicin. The combination with doxorubicin exhibited the greatest reduction in tumour volume and was well tolerated.

The second study was a pilot in advance of the more comprehensive cardiomyopathy study, which is currently underway. This study is to assess the potential cardioprotective efficacy of Xolatryp in patients receiving doxorubicin.

Preliminary biomarker data in this pilot study showed numerically lower mean cardiac troponin I, a clinically relevant marker of cardiac injury, relative to the doxorubicin plus vehicle control group. The study confirmed the feasibility and tolerability of the intended subcutaneous dosing regimen and will inform dose selection for Nyrada's larger cardiomyopathy (cardioprotection) study. This larger study commenced in late 4QFY2026 and is expected to read out in mid 1QFY2027.

Finance, Capital, and Corporate

As at 30 June 2026, Nyrada had a cash position of AU$8.39 million (AU$6.74 million as at 31 March 2026). Total cash operating outflows for the June 2026 quarter were approximately AU$1.66 million, offset by AU$60,000 interest income received and receipt of R&D tax incentive.

As per prior years, the Company applied for the Australian Government's R&D Tax incentive for the financial year ended 30 June 2025 with an amount of AU$2.46 million received during the quarter. Additionally, AU$0.83 million was received from exercise of options during the quarter, (AU$0.51 million for March 2026 quarter)

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C were approximately AU$219,000 (approximately AU$219,000 for the quarter ending 30 March 2026) and includes Director fees for the Chair and Non-Executive directors (including superannuation) and salary and superannuation for the Managing Director/CEO.

During the quarter, the company received formal Notice of Allowance from the US Patent Office, with the patent published and grant expected imminently. The granted patent will provide intellectual property protection within the US over the chemical structure of Xolatryp and associate analogues, with a 20-year term from the September 2024 filing date.

-ENDS-

About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive calcium entry related to multiple disease pathologies.

A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed and a Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI.

Key Links:

Latest Corporate Presentation - https://bit.ly/4v0QgXE

Foundation Studies

- GLP study results – https://bit.ly/4d8VYkX
- Phase I trial results – https://bit.ly/3Nt0GzH

Cardiac Studies

- Phase IIa PROTECT-MI website - https://www.protect-mi.com
- Phase IIa study fact sheet – https://bit.ly/4bcDlKj
- Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ
- Preclinical cardioprotection study 1b - https://bit.ly/4rmOsXn
- Preclinical cardioprotection study 2 - https://bit.ly/40jHpUg

Oncology Studies

- Preclinical anti-tumour study - https://bit.ly/49rWOa0
- Preclinical cardioprotection pilot study - https://bit.ly/3QS1VKm

Stroke Study

- Preclinical stroke study - https://bit.ly/4sygHmH

TBI Study

- Preclinical TBI study - https://bit.ly/40fhrRT

About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Nyrada Inc.	
ABN	**Quarter ended ("current quarter")**
54 625 401 818	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(1,032)	(4.390)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(338)	(1,289)
	(f) administration and corporate costs	(289)	(1,434)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	60	152
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	2.447	2,447
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**848**	**(4,514)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(7)	(9)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(7)**	**(9)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	8,121
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	828	2,293
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(2)	(414)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**826**	**10,000**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	6,735	2,931
4.2	Net cash from / (used in) operating activities (item 1.9 above)	848	(4,514)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(7)	(9)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	826	10,000
4.5	Effect of movement in exchange rates on cash held	(17)	(23)
4.6	**Cash and cash equivalents at end of period**	**8,385**	**8,385**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	3,835	4,206
5.2	Call deposits	4,500	2,529
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**8,385**	**6,735**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	219
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount at 6.1 includes Director fees for the Chair and Non-Executive directors (including superannuation) and salary and superannuation for the CEO/Managing Director

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	848
8.2	Cash and cash equivalents at quarter end (item 4.6)	8,385
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	8,385
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**N/A**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:
N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:
N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:
N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

27 July 2026

Date: .....

By order of the Board

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.